Both cisplatin and carboplatin treatments in A549 and H1299, two human non-small cell lung cancer cell lines, led to the obvious accumulation of UBE2F in a dose-dependent manner, but not other neddylation components (e.g., E1: NAE1 and UBA3; E2: UBE2M; E3: RBX1 and RBX2) (Fig. 1A and Supplementary Fig. 1A). The gene discussed is UBE2M; the disease is non-small cell lung carcinoma.